Overview

Until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of either aspirin or clopidogrel monotherapy. A new era is emerging in which, by adding low-dose DOACs to low-dose aspirin, medical therapy may reduce the need for major vascular surgery or endovascular procedures. In this Virtual Expert Roundtable, the faculty will discuss the latest evidence, indications, and guideline-based utilization of dual antiplatelet therapy. In addition to an in-depth look at PAD therapy, participants in this session will receive insights on the latest in secondary prevention options for ESUS and a review of proper dosing for long-term anticoagulation to prevent recurrent events in patients with venous thromboembolic disease. 

Learning Objectives

  • Identify patients with PAD and ensure appropriate treatment to prevent the substantial morbidity and mortality associated with the disease
  • Recognize the evolving role of DOACs, in combination with antiplatelet therapy, as secondary prevention for patients with cardiovascular disease, as demonstrated by the COMPASS trial
  • Employ proper dosing of long-term anticoagulation to prevent recurrent events in patients with provoked venous thromboembolic disease 

Faculty Disclosures

Gregory Piazza, MD, MS

Advisory Board for Pfizer Inc. and Portola Pharmaceuticals, Inc. Contracted Research for Bayer; Bristol-Myers Squibb Company; BTG; Daiichi Sankyo, Inc.; and Janssen Scientific Affairs, LLC.  

Umberto Campia, MD, MS, FACC, FAHA

No financial relationships to disclose.  


Disclosures

John D. Fisher, MD (Peer Reviewer)
Professor, Department of Medicine (Cardiology)
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY 

Victor B. Hatcher, PhD (CME Reviewer)
Associate Dean for Continuing Medical Education
Professor, Department of Medicine 
Professor, Department of Microbiology
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

CONFLICT OF INTEREST DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, Albert Einstein College of Medicine requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. Albert Einstein College of Medicine resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities. 


CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 


Designation Statement

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Obtaining Credit

Once you have completed the activity, please click the “next” button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the “submit” button to complete the evaluation questions and proceed to the claim credit screen.

Commercial Supporter

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Education Partner

North American Thrombosis Forum


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Albert Einstein College of Medicine, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Accredited Provider
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Disclosures and Conflict of Interest
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relevant relationship(s) with a pharmaceutical or equipment company.*  Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Victor B. Hatcher, PhD, and the staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine have no relevant conflict of interest with commercial companies, related directly or indirectly, to this educational activity.

*The ACCME defines a Commercial Interest as an entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interest. 

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Albert Einstein College of Medicine, pmiCME or DBC Pri-Med, LLC. 

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.